Wyss Zurich
Deana Mohr-Haralampieva is currently the CEO & co-founder of MUVON Therapeutics AG. Prior to this role, Deana worked as a Project Leader at Wyss Zurich and as a UZH Entrepreneur Fellow at the University of Zurich. Deana has a background in urologic tissue engineering, stem cell therapy, and pharmaceutical sciences. Deana holds a Dr.sc.ETH degree from ETH Zurich in Radiopharmaceutical Sciences, Tissue Engineering, and Stem Cell Therapies. Deana also has a Master's degree in Cellular and Molecular Biology from the University of Konstanz, where Deana previously worked as a Laboratory Assistant and Research Associate. Deana's expertise includes clinical research, project management, grant writing, and coordination of international consortiums.
Wyss Zurich
Wyss Zurich is a joint research and development center of the University of Zurich and the ETH Zurich, made possible by a generous donation from the Swiss entrepreneur and philanthropist Dr. hc. mult. Hansjörg Wyss. The mission of Wyss Zurich is to drive the clinical translation and technology transfer of outstanding scientific discoveries into new therapies for patients and breakthrough innovations in the emerging fields of Regenerative Medicine, Robotics and Medical Devices/Bionics Technologies. Wyss Zurich brings together some of the world’s leading experts to form multidisciplinary teams, pooling their knowledge and expertise.